Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
Total Valuation
Marker Therapeutics has a market cap or net worth of $12.90M. The enterprise value is -$1.13M.
Market Cap$12.90M
Enterprise Value-$1.13M
Share Statistics
Marker Therapeutics has 11,314,835 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,314,835
Owned by Insiders41.03%
Owned by Institutions29.02%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -280238.84%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-280238.84%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee1.32M
Profits Per Employee-2.15M
Employee Count5
Asset Turnover0.30
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is -2.60. Marker Therapeutics’s PEG ratio is 0.09.
PE Ratio-2.60
PS Ratio0.00
PB Ratio0.85
Price to Fair Value<0.01
Price to FCF-1.00
Price to Operating Cash Flow-0.98
PEG Ratio0.09
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 6.59M and earned -10.73M in profits. Earnings per share was -1.19.
Revenue6.59M
Gross Profit6.59M
Operating Income-11.12M
Pretax Income-10.68M
Net Income-10.73M
EBITDA-10.68M
Earnings Per Share (EPS)-1.19
Cash Flow
In the last 12 months, operating cash flow was -12.57M and capital expenditures 0.00, giving a free cash flow of -12.57M billion.
Operating Cash Flow-12.57M
Free Cash Flow-12.57M
Free Cash Flow per Share-1.11
Dividends & Yields
Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change-70.99%
50-Day Moving Average1.17
200-Day Moving Average2.51
Relative Strength Index (RSI)47.45
Average Volume (3m)36.83K
Important Dates
Marker Therapeutics upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Marker Therapeutics as a current ratio of 6.36, with Debt / Equity ratio of 0.00%
Current Ratio6.36
Quick Ratio6.36
Debt to Market Cap0.00
Net Debt to EBITDA1.80
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marker Therapeutics has paid 49.95B in taxes.
Income Tax49.95B
Effective Tax Rate-4.68K
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is -0.82, with an EV/FCF ratio of -0.80.
EV to Sales1.33
EV to EBITDA-0.82
EV to Free Cash Flow-0.80
EV to Operating Cash Flow-0.80
Balance Sheet
Marker Therapeutics has $13.69M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$13.69M billion.
Cash & Marketable Securities$13.69M
Total Debt$0.00
Net Cash-$13.69M
Net Cash Per Share-$1.21
Tangible Book Value Per Share$2.07
Margins
Gross margin is 48.66%, with operating margin of -168.69%, and net profit margin of -162.82%.
Gross Margin48.66%
Operating Margin-168.69%
Pretax Margin-162.06%
Net Profit Margin-162.82%
EBITDA Margin-162.06%
EBIT Margin-68.69%
Analyst Forecast
The average price target for Marker Therapeutics is $10.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.25
Price Target Upside799.12% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-3.23%
EPS Growth Forecast38.05%